ArticleJournal of virology2022
New Assay Reveals Vast Excess of Defective over Intact HIV-1 Transcripts in Antiretroviral Therapy-Suppressed Individuals.
Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size.JCI insight · 2024Trial
- HIV DNA and transcription before and after ART in natural controllers compared to noncontrollers.Journal of virology · 2026Article
- Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial.Nature communications · 2026Article
- HIV persistence in tissues on dolutegravir-based therapy is not associated with resistance mutations to dolutegravir.Communications medicine · 2026Article
- Tools to Quantify and Characterize the Persistent Reservoir in People with HIV-1: Focus on Non-B Subtypes.Viruses · 2026Review
- Ultra-low level HIV p24 drives immune activation in antiretroviral therapy-treated people living with HIV.Communications medicine · 2025Article
- Differential decreases in various HIV DNA regions and HIV transcripts after ART initiation during chronic infection.Journal of virology · 2025Article
- Longitudinal changes in the transcriptionally active and intact HIV reservoir after starting ART during acute infection.Journal of virology · 2025Article
- HIV-1 latency reversal agent boosting is not limited by opioid use.JCI insight · 2024Article
- Article
- HIV-1 latency reversal agent boosting is not limited by opioid use.medRxiv : the preprint server for health sciences · 2024Article
- The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy.The Journal of infectious diseases · 2024Article
- Measuring Human Immunodeficiency Virus Reservoirs: Do We Need to Choose Between Quantity and Quality?The Journal of infectious diseases · 2024Review
- Validation of digital droplet PCR assays for cell-associated HIV-1 DNA, HIV-1 2-LTR circle, and HIV-1 unspliced RNA for clinical studies in HIV-1 cure research.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2024Article
- Article
- Use of laboratory-developed assays in global HIV-1 treatment-monitoring and research.Scientific reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Most of the HIV DNA in infected individuals is noninfectious because of deleterious mutations. However, it is unclear how much of the transcribed HIV RNA is potentially infectious or defective. To address this question, we developed and validated a novel intact viral RNA assay (IVRA) that uses droplet digital reverse transcriptase PCR (dd-RT-PCR) for the commonly mutated packaging signal (Psi) and Rev response element (RRE) regions (from the intact proviral DNA assay [IPDA]) to quantify likely intact (Psi
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.